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Objective: Completion of the Fontan procedure is frequently performed by using an
extracardiac conduit between the inferior vena cava and the pulmonary artery. Most
centers use a polytetrafluoroethylene graft for the extracardiac conduit, and because
re-endothelialization is unlikely, anticoagulation is used for a variable period. This
study explores the use of an alternate large-caliber venous conduit.
Methods: The superior vena cava was replaced in 8 minipigs with either a polytet-
rafluoroethylene interposition graft (2 pigs) or a depopulated (acellular), cryopre-
served superior vena caval homograft (6 pigs). After 6 months, the animals were
killed, and the grafts were examined for patency and histology, including immu-
nostaining. No anticoagulation was used.
Results: Polytetrafluoroethylene grafts have a cross-sectional luminal narrowing,
ranging from 16% to 40%. Histology showed only partial intimal ingrowth, with
excessive subendothelial fibrosis and early calcification. In contrast, the depopulated
venous homografts showed minimal luminal narrowing, ranging from 2% to 9%.
These grafts were completely repopulated by the recipient with an endothelial
lining, which stained positively for factor VIII, and a subendothelial region appro-
priately recellularized by myofibroblasts, which stained positively for smooth mus-
cle actin and procollagen. There was no evidence of an immune response to the
venous homografts, as judged by staining for T-cell surface antigen, CD4, and CD8.
Thrombus was not seen in any of the grafts.
Conclusion: Depopulated, cryopreserved vena caval homografts might be superior
conduits for cavopulmonary connection during completion of the Fontan operation
by using the extracardiac conduit technique.
Until recently, the need for replacement of large veins was limitedand usually involved tumor resection or trauma. The recent adventof the extracardiac Fontan procedure with inferior cavopulmonaryconnection requiring a conduit extension has raised interest inlarge-caliber venous vascular prostheses.
Grafting of a larger-caliber vein has usually been performed with a polytetra-
fluoroethylene (PTFE) graft with or without external ring support. Although the
results have been satisfactory, complete re-endothelialization of these conduits has
been questionable. Without a well-healed endothelium, such conduits are at risk for
platelet fibrin aggregates that lead to fibrointimal thickening, as well as possible
thromboembolism. For this reason, anticoagulation, with its attendant risks, has
often been used after PTFE grafting.
Cryopreserved homograft tissue is an alternate choice for major vein replace-
ment. Because of the diameter and length of the graft that is usually needed, aortic
tissue has been used most frequently. Unfortunately, aortic homografts have tended
to degenerate over time and develop a thickened and calcified vessel wall that could
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become obstructive or thrombogenic. Several studies have
suggested that this process might be due to the homograft
recipient’s immune response to the viable homograft donor
cells.1-3
Antigen reduction of homograft tissue by means of cell-
depopulation techniques has recently been introduced. De-
populated pulmonary homografts have been shown to be
less antigenic than their viable counterparts.4 In animal
studies these depopulated conduits have shown rapid re-
population with functioning host cells and a significantly
decreased tendency to degenerate and calcify.5-7 A large-
diameter venous conduit that would repopulate with recip-
ient cells to form a normally functioning vascular endothe-
lium and a renewable connective tissue matrix would be
ideal. We have therefore investigated depopulated cryopre-
served vena caval homograft tissue used to replace the
superior vena cava (SVC) in a large-animal model.
Materials and Methods
The investigation was carried out in 8 Yucatan micropigs, 7 of
which completed the full-term protocol. The median age and
weight of the animals was 8.6 months (7.7-11.7 months) and 98 lbs
(82-115 lbs). There was essentially no growth in the 6-month
interval to death, with median weight at the time of death of 98 lbs
(85-112 lbs). Two animals had replacement of the SVC with a
PTFE graft (Gore-Tex graft; W. L. Gore & Associates, Inc, Flag-
staff, Ariz). The remaining 6 pigs had the SVC replaced with a
depopulated, cryopreserved SVC homograft. Animals were kept
for 6 months. At death, the SVC graft was explanted for histologic
evaluation and immunostaining (Figure 1).
All pigs in the study received humane care in compliance with
the “Guide for the Care and Use of Laboratory Animals” prepared
by the Institute of Laboratory Animal Resources and published by
the National Academy Press, revised 1996.
Preparation of Depopulated SVC Allografts
The SVC was harvested from 6 juvenile farm pigs (diameter,
18-20 mm) and then transported in iced physiologic buffer for
depopulation processing and cryopreservation. The tissue was
treated by using a propriety method (SynerGraft; CryoLife, Inc,
Kennesaw, Ga) to eliminate cells in the vessel wall. The steps
included cell lysis in hypotonic solution, enzymatic digestion of
nucleic acid, and washout in an isotonic neutral buffer. Once
depopulated, the veins were cryopreserved and stored in liquid
nitrogen until implantation.
SVC Replacement
SVC replacement was carried out through a modified manubrium-
sparing sternotomy. After heparinization, vascular clamps were
secured, and the SVC was resected. The native SVC was between
16 and 18 mm in diameter. The SVC was then replaced, with the
anastomosis completed with a 6-0 running polypropylene suture
technique.
Two pigs received an 18-mm PTFE graft 3 to 4 cm in length.
Six pigs had SVC replacement with a depopulated cryopreserved
SVC homograft that was 18 to 20 mm in diameter and 3 to 4 cm
in length. The animals were given a 5-day course of prophylactic
antibodies postoperatively (first-generation cephalosporin).
All of the animals survived the operation and were maintained
without anticoagulation. One animal died from pneumonia at an
interval of 2 months after the operation. Unfortunately, the SVC
was not explanted in a timely manner and was lost for analysis.
The remaining 7 animals survived to 6 months, at which time they
were killed, followed by removal of their SVC grafts by means of
re-entry sternotomy.
Microscopic Analysis (Histology-Immunochemistry)
Specimens of porcine SVC were evaluated before and after de-
population treatment (SynerGraft) for histology and immunochem-
istry analysis.
The explanted SVC replacement grafts were dissected and
divided between buffered neutral formalin or cryosectioning me-
dium. The fixed specimens were then cut into proximal, mid, and
distal conduit segments and then embedded in paraffin and stained
with hematoxylin and eosin. Representative sections were exam-
ined for patency, with measurement of cross-sectional luminal
narrowing assessed by using a planimetry technique.
A separate portion of the explanted graft wall was equilibrated
in 15% sucrose in phosphate-buffered saline for at least 1 hour at
4°C and then frozen in embedding compound (O.C.T. compound;
Tissue-Tek, Torrance, Calif) for cryosectioning and immunostain-
ing. Monoclonal antibodies were used to make several determina-
tions, including the following: for cellular immune response to the
graft, T-cell surface antigen (anti-TCR 1 86D; VMRD, Pullman,
Wash), cytotoxic T cells (anti-CD8; Zymed Labs, San Francisco,
Calif), and helper T cells, macrophages, and other inflammatory
cells (anti-CD4; Center for Animal Biotechnology, University of
Melbourne, Melbourne, Australia); for cellular identification and
function, smooth muscle actin (IgG2A; Vector, Burlingame, Cal-
if), endothelial cells (anti-factor VIII; Sigma, St Louis, Mo),
monocytes and macrophages (DH59B, VMRD, Inc), class I and
class II major histocompatibility antigens (anti-MHC I and II,
VMRD, Inc), and procollagen type I production (anti-procollagen
SP1.D8; Developmental Studies Hybridoma Bank, University of
Iowa, Iowa City, Iowa).
Antibody binding was visualized colorimetrically by using
peroxidase-conjugated antibody and reaction with 3, 3-diamino-
benzimide.
Figure 1. Outcomes of SVC replacement in 8 minipigs.
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Results
Macroscopic Graft Appearance
At explantation, there was a moderate degree of generalized
scarring around the SVC graft. There was no difference in
the degree of reaction when comparing the PTFE with the
homograft conduits. All of the grafts were patent and pli-
able, with no visible evidence of calcification. Inspection of
the lumen of one of the PTFE conduits suggests moderate
narrowing near the distal anastomosis site.
Microscopic Appearance of Normal and Depopulated
Vena Caval Tissue
Hematoxylin and eosin–stained sections of the normal and
depopulated cryopreserved porcine SVC tissues were ob-
tained (Figure 2). Untreated tissue showed a normal cellular
content and distribution pattern. The depopulation treatment
resulted in a near-total removal of histologically demonstra-
ble cells throughout the tissues. What remained was con-
nective tissue matrix, which was primarily composed of
structural collagen, elastin, and smooth muscle actin.
Immunostaining directed to identify reaction of specific
cell types demonstrated a normal cellular content and dis-
tribution pattern in the untreated SVC tissue. Factor VIII–
positive endothelial cells lined the luminal surface and that
of the microvasculature, which was dispersed regularly
throughout the media. Smooth muscle actin–positive cells
were found throughout the structure, with the highest con-
centration of positive cells in the intimal layer and surround-
ing the microvascular structures. MHC I–positive cells were
scattered throughout the graft, as were MHC II–positive
cells, although these had a higher concentration around
endothelial cell–positive areas. Cells staining positive for
antigen to granulocytes and macrophages (anti-GMI) were
scattered throughout the untreated tissue.
Immunostaining of preimplantation depopulated cryo-
preserved SVC showed virtually no reaction to any of the
antibodies used.
Assessment of Luminal Narrowing of Postimplantation
SVC Grafts
Cross-sectional luminal area was measured within the prox-
imal, mid, and distal regions of the SVC replacement grafts
when explanted at 6 months. Maximal narrowing was noted
to be 16% and 40% for the 2 PTFE control animals. The
maximal cross-sectional luminal narrowing for the depop-
ulated cryopreserved SVC allograft was a median of 6% and
ranged from 2% to 9% among the 5 pigs that survived to 6
months.
Microscopic Appearance of Explanted SVC Grafts
The 2 PTFE grafts showed only partial intimal ingrowth,
with excessive fibrosis and early calcification. There was a
paucity of endothelial cells, which formed an inconsistent
Figure 2. Histology of normal and depopulated cryopreserved SVCs. Left image shows a normal, untreated porcine
SVC stained with hematoxylin and eosin. Right image demonstrates a depopulated, cryopreserved SVC before
implantation. Only the connective tissue matrix remains, with very few viable cells.
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lining. The thickened ingrowth stained positively for
smooth muscle actin.
Histology determined by means of hematoxylin and eo-
sin staining of the postimplantation depopulated cryopre-
served SVC allografts demonstrated re-establishment of a
normal-appearing cellular pattern with microvasculature
throughout. The appearance was comparable with that of the
normal porcine SVC tissue prepared as a control. Evaluation
with immunohistochemical stains demonstrated factor VIII–
positive cells (endothelial cells), smooth muscle actin, MHC
I and MHC II, and granulocytes and macrophages (Figure
3). The explanted grafts showed the same pattern of staining
as seen in the normal SVC. Endothelial cells were demon-
strated in the lumen around the entire graft and around
microvascular structures. Smooth muscle actin–positive
cells were found throughout the intimal lining, arterioles,
and venules in the appropriate pattern.
Comparison of untreated SVC and depopulated postim-
plantation grafts with antibodies to detect a cellular immune
response by using anti-CD8, anti-CD4, and anti-TCR I
demonstrated no increase in immune positive cells in the
depopulated grafts that had been implanted for 6 months.
Cellular biosynthetic function was demonstrated with
procollagen type I staining. The normal SVC control had a
very low level of procollagen production, which was found
primarily in a small number of cells scattered in the adven-
titia. The explanted homografts showed enhanced procolla-
gen production, with some areas of numerous positively
stained cells located primarily in the graft media.
Discussion
Interest in vena caval replacement grafts has been rekindled
by the emergence and now frequent use of the extracardiac
conduit Fontan repair. Although several types of tube grafts
have been used as the interposition extension of the inferior
vena cava to the pulmonary artery, including Dacron 8 and
aortic homograft tissue,9 the majority of cases have been
done with PTFE conduits.
Several studies have documented the outcomes of PTFE
used for prosthetic replacement of the thoracic vena cava.
Animal studies by Fiore and colleagues10 reported in 1982
showed excellent short-term patency of PTFE SVC grafts
and suggested that grafts with external ring support might
be superior. The potential advantage of spiral supported
grafts was further demonstrated by Masuda and coworkers11
in long-term animal studies. These showed better patency
and more favorable re-endothelialization at 3 years among
spiral supported versus unsupported PTFE conduits.
Investigation into the healing process of PTFE grafts
used for replacement of large veins has been studied in
animals by Kogel and colleagues.12 Primary formation of
intramural thrombogenic matrix in the prosthetic wall was
thought to induce tissue and capillary invasion from sur-
rounding tissue by means of chemotactic release of growth
factors. This in turn led to multifocal endothelial cell in-
growth from transprosthetic channels.
Dartvelle and associates13 have reported on the long-
term performance after PTFE graft replacement of the SVC
in patients undergoing resection of mediastinal tumors.
Among 15 patients followed for a median of 31 months, the
3- and 5-year actuarial graft patency was 86%. Of interest is
the authors’ recommendation that patients be given warfarin
sodium (Coumadin) for 6 months after graft placement.
Marcelletti and coworkers8 have provided long-term fol-
low-up of PTFE conduits used for extracardiac Fontan
repair. Serial magnetic resonance imaging studies carried
out in 30 patients showed a mean reduction of the internal
conduit diameter of 18%  8% during the first 6 months of
implantation. There was no progression over the following
5 years. Even the maximal internal diameter reduction of
32%  8% found among the 10 patients with the most
obstruction did not progress over time. It is of interest that
the 2 PTFE conduits placed in our pigs had luminal nar-
rowing of 16% and 40%, respectively, which falls within
Figure 3. Immunostaining for factor VIII and smooth muscle actin
in explanted homograft. Solid arrows point to endothelial cells
that have stained positively for factor VIII. They are in the central
lumen of the conduit and in the lining of the microvasculature of
the matrix. The open arrow indicates positive staining for smooth
muscle actin in the intimal lining, as well as around arterioles
and venules.
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the range of what has been observed clinically by Marcel-
letti and coworkers.
Although there are a few reports9 of the use of cryopre-
served aortic homograft tissue for vena caval replacement,
there is no reported long-term follow-up on the fate of this
conduit. In general, aortic homograft tissue has shown a
tendency to degenerate, calcify, and become obstructive
when used in the right ventricular outflow tract. Structural
degeneration is also known to occur more frequently and
earlier in younger recipients.14,15 Evidence is mounting that
cryopreserved homograft deterioration might be due to both
a cellular and humoral immune response of the recipient.16
However, there is no agreement on the relationship of the
immune response as measured by antibody production on
graft function, with some authors3 demonstrating a correla-
tion between antigen production and structural degeneration
and others17,18 finding no correlation. What does seem to be
clear is that standard cryopreserved homografts tend to lose
donor cellularity and do not revascularize or recellularize
from the recipient.19 Thus these conduits would not be
expected to develop the antithrombogenic effects of re-
endothelialization nor would they regenerate their connec-
tive tissue matrix.
In contrast to standard cryopreserved homograft tissue,
depopulated conduits show virtually no humoral immune
response in patients, as measured by means of Panel-reac-
tive antibody analysis, at 1 and 3 months after implanta-
tion.4 By using an animal model, a process of recellulariza-
tion and adaptive remodeling has also been shown to take
place in these depopulated grafts. This was true both for
depopulated allograft and xenograft valved conduits, in
which functional repopulation of the matrix, including leaf-
let tissue, was demonstrated.20
It is our belief that a conduit that has been repopulated
with functional recipient cells will be the optimal graft for
replacing or extending major veins. Whether these grafts
will have the ability to grow remains in question and is the
subject of ongoing study. The need for anticoagulation
might also be mitigated by the adaptive remodeling of an
intact endothelium, although this remains to be proved.
Whether anticoagulation should be managed with an anti-
platelet agent or with warfarin has not yet been resolved.
Anticoagulation would most likely be suggested for several
months while repopulation was in progress. Avoidance of
anticoagulation is of particular importance in children, in
whom achieving a consistently increased clotting time is
often difficult.
On the basis of our experience in this animal study, we
believe that depopulated cryopreserved homograft tissue is
the best alternative for major vein grafting. Clinical use of
this technique is under consideration.
Because the number of animals available for investiga-
tion was limited, it was elected to do only 2 control studies
with PTFE conduits. This number was believed to be ade-
quate because, as noted above, a number of animal studies
have evaluated PTFE grafts in similar SVC replacement
models. Additionally, human studies have documented the
outcomes of PTFE venous grafts, and the results in our 2
control animals were similar to what has been previously
found. Thus, we concluded that our model was valid for
demonstrating problems with graft obstruction if there was
a propensity for this to occur. It must be acknowledged,
however, that the number of PTFE control animals was very
small and could not yield statistically significant data.
Conduits were in place for 6 months before explantation
and investigation. It is possible that there could be degen-
eration and progressive obstruction over longer time peri-
ods; however, as noted in our discussion, the literature
suggests that narrowing of major vein conduits appears to
occur in the first 6 months after implantation and does not
significantly progress between that point and 3 years. It was
this information that led us to investigate our grafts at 6
months. It is possible, however, that with longer follow-up,
additional obstruction, thrombus, or both could form. Ex-
perience with standard cryopreserved homografts suggests
that destruction and obstruction is an ongoing event. There-
fore, longer-term follow-up is needed.
References
1. Rajani B, Mee RB, Ratliff NB. Evidence for rejection of homograft
cardiac valves in infants. J Thorac Cardiovasc Surg. 1998;115:111-7.
2. Baskett RJ, Ross DB, Nanton MA, et al. Factors in the early failure of
cryopreserved homograft pulmonary valves in children; preserved
immunogenicity. J Thorac Cardiovasc Surg. 1996;112:1170-9.
3. Dignan R, O’Brian M, Hogan P, et al. Influence of HLA matching and
associated factors on aortic valve homograft function. J Heart Valve
Dis. 2000;9:504-11.
4. Elkins RC, Lane MM, Capps SB, et al. Humoral immune response to
allograft valve tissue pretreated with an antigen reduction process.
Semin Thorac Cardiovasc Surg. 2001;13(Suppl I):I82-6.
5. O’Brien MF, Goldstein S, Walsh S, et al. The SynerGraft valve: a new
acellular (nongluteraldehyde-fixed) tissue heart valve for autologous
recellularization first experimental studies before clinical implantation.
Semin Thorac Cardiovasc Surg. 1999;11:194-200.
6. Elkins RC, Dawson PE, Goldstein S, et al. Decellularized human valve
allografts. Ann Thorac Surg. 2001;71:5428-32.
7. Goldstein S, Clarke DR, Walsh SP, et al. Transpecies heart valve
transplant: advanced studies in a bioengineered xeno-autograft. Ann
Thorac Surg. 2000;70:1962-9.
8. Marcelletti CF, Iorio FS, Abella RF. Late results of extracardiac
Fontan repair. Semin Thorac Cardiovasc Surg. 1999;2:131-41.
9. Azakie A, McCrindle BW, VanArsdell GV, et al. Extra cardiac conduit
versus lateral tunnel cavopulmonary connections at a single institution:
impact on outcomes. J Thorac Cardiovasc Surg. 2001;122:1219-28.
10. Fiore A, Brown J, Cromartic B, et al. Prosthetic replacement for the
thoracic vena cava. J Thorac Cardiovasc Surg. 1982;84:560-8.
11. Masuda H, Ogata T, Kibuchi K, Tanaka S. Longevity of expanded
polytetrafluoroethylene grafts for superior vena cava. Ann Thorac
Surg. 1989;48:376-80.
12. Kogel H, Vollmar J, Cyba-Altunbay S, et al. New observations on the
healing process in prosthetic substitution of large veins by micro-
porous grafts—animal experiments. Thorac Cardiovasc Surg. 1989;
37:119-24.
13. Dartevelle P, Chapelier A, Pastorino L, et al. Long term follow-up
after prosthetic placement of the superior vena cava combined with
Surgery for Congenital Heart Disease Wells et al
502 The Journal of Thoracic and Cardiovascular Surgery ● August 2003
CH
D
resection of mediastinal-pulmonary malignant tumors. J Thorac Car-
diovasc Surg. 1991;102:259-65.
14. Yacoub M, Rasmi NRH, Sundt TM, et al. Fourteen-year experience
with homovital homografts for aortic valve replacement. J Thorac
Cardiovasc Surg. 1995;110:186-94.
15. Niwaya K, Knott Craig CJ, Lane MM, et al. Cryopreserved homograft
valves in the pulmonary position: risk analysis for intermediate term
failure. J Thorac Cardiovasc Surg. 1999;117:141-7.
16. Hogan P, Duplock L, Green M, et al. Human aortic valve allografts
elicit a donor specific immune response. J Thorac Cardiovasc Surg.
1996;112:1260-6.
17. Smith J, Hornick P, Rasmi N, et al. Effect of hla mismatching and
antibody status on “homovital” aortic valve performance. Ann Thorac
Surg. 1998;66:S212-5.
18. Hawkins J, Breinholt J, Lambert L, et al. Class I and class II anti-hla
antibodies after implantation of cryopreserved allograft material in
pediatric patients. J Thorac Cardiovasc Surg. 2000;119:324-30.
19. Mitchell RN, Jonas RA, Schoen FJ. Pathology of explanted cryopre-
served allograft heart valves: comparison with aortic valves from
orthotopic heart transplants. J Thorac Cardiovasc Surg. 1998;115:118-
27.
20. Elkins RC, Goldstein S, Hewitt C, et al. Recellularization of heart
valve grafts by a process of adaptive remodeling. Semin Thorac
Cardiovasc Surg. 2001;13(Suppl 1):87-92.
Discussion
Dr Davis C. Drinkwater (Nashville, Tenn). I have a couple of
questions.
If I could set the basis for doing this study, have you, in your
clinical series, had issues with clotted PTFE grafts or early failure
with your grafts? Do you use aspirin or warfarin early on in your
clinical practice, and did you do so with these piglets? I guess most
people would use aspirin, if not warfarin, at least early in the
postoperative course.
What was the size mismatch relative to the adult human? For
example, we have tried to put in at least a 22-mm graft as an
extracardiac conduit. Was this a size mismatch that might have
created flow-and-eddy problems that could potentially create early
stenosis issues? I am wondering about the size mismatch being a
cause. Setting that aside, potentially where will you harvest from
the human if the organs that are taken are the liver and the heart?
What portion of the cava is available, the renal, the suprarenal?
Dr Wells. Thank you for the questions.
We have not really observed a problem with thrombosis. We
were concerned about the reports coming from Italy that there
might be up to a 30% to 40% cross-sectional luminal reduction in
the serially magnetic resonance imaging–studied vena caval ex-
tensions for Fontan completion. Therefore that in and of itself was
the impetus to determine whether there is something better. Also,
we have been concerned in our practice about leaving patients
without aggressive anticoagulation for the first at least 6 months
after putting in the PTFE graft. Therefore, you are going to subject
a child to at least 6 months of anticoagulation, which you might be
able to avoid. And I should add that in these studies there was no
anticoagulation. Thanks for pointing that out.
As far as the size of the homografts, we tried to use clinically
appropriate sizes. Therefore, these were 18- to 20-mm homografts,
3 cm to 4 cm in length, and we think that the typical patient in
whom we are doing this for Fontan completion gets a conduit of 18
to 20 mm and about 5 cm in length. Therefore we believed that this
was clinically appropriate.
Finally, either the innominate vein in a larger donor or poten-
tially the inferior vena cava, which will have more branches, could
be sites. The infrarenal cava could be a site for harvesting, and we
are just getting interested in investigating the best place from
which to take that venous tissue.
Dr Vaughn A. Starnes (Los Angeles, Calif). You are implying,
then, that this would be homograft tissue and not xenograft tissue?
Dr Wells. There is evidence currently that there is no differ-
ence between homograft and xenograft for the depopulated tissues.
That is animal work that is fairly convincing. However, I think if
you want to use this clinically during our foreseeable lifetime, we
probably need allografts. We probably need human tissue to get
this going.
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